Efficacy and safety of PCSK9 monoclonal antibodies in older patients: A real-world registry
Efficacy and safety of PCSK9 mAbs are comparable for patients ≥70 years and patients <70 years in a real-world study.
Authors
- Majon Muller (ORCID: https://orcid.org/0000-0002-7127-6413)
- Jeanine E. Roeters van Lennep (ORCID: https://orcid.org/0000-0001-6870-9962)
- Melvin Lafeber (ORCID: https://orcid.org/0000-0001-7061-6415)
- Janneke W.C.M. Mulder (ORCID: https://orcid.org/0009-0003-9837-726X)
- Francesco Mattace‐Raso (ORCID: https://orcid.org/0000-0002-1688-6497)
- Annette M.H. Galema‐Boers
- Ruben J M Mijnster
Institutions
- Erasmus MC (NL)
- Erasmus MC Cancer Institute (NL)
- Amsterdam University of Applied Sciences (NL)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- Atherosclerosis
- Published
- 2025-05-26
- DOI
- https://doi.org/10.1016/j.atherosclerosis.2025.120229
- Citations
- 1
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 2.01